Companies: 10,795·Total market cap: $144.5T

BGM Group Ltd.

BGM Group Ltd.

BGMNASDAQHealthcare● Active

$0.29

$-0.03(-10.49%)

Market Cap$58381400

P/E Ratio—

52W High$17.17

52W Low$0.256

Avg Volume336K

Open$0.31

Beta1.82

股票排行：Drug Manufacturers - Specialty & Generic·Healthcare·查看全部市值排行 →

BGM Group Ltd.（BGM）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · BGM · 截至 Jun 8, 2026

关键指标

EPS (TTM)—Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)—Full revenue history

Dividend Yield4.55%Dividend history

Shares Outstanding7.2MShares outstanding history

Next EarningsTBAEarnings history

探索 BGM Group Ltd. 数据

分析师预测—

营收$25.1M-45.99%

盈利EPS $-0.20+81.48%

财务快照

FY 2024Revenue$25.1M▼ 45.99% YoY

202220232024

FY 2024Net Income-$1.4M▲ +81.46% YoY

202220232024

FY 2024EPS$-0.20▲ +81.48% YoY

202220232024

TTM:View income statement →

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

$0.29-10.49%$58.4M #2

ANI Pharmaceuticals, Inc.

$81.11+2.41%$1.8B #3

Avadel Pharmaceuticals plc

$21.64+0.00%$2.1B #4

Clover Health Investments, Corp.

$3.83-4.01%$2.0B #5

Edgewise Therapeutics, Inc.

$35.59-4.41%$3.8B #6

Structure Therapeutics Inc.

$37.58-3.79%$2.2B

股票表现

1D-10.49%

1W-10.85%

1M-0.68%

3M-72.02%

YTD-92.11%

1Y-97.80%

5Y-94.71%

关于 BGM Group Ltd.

CEOChen Xin

IPO DateJan 24, 2003

Employees298

CountryCN

Websitebgm.ltd

BGM Group Ltd. BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice prod…

Drug Manufacturers - Specialty & Generic HealthcareNASDAQCN

关于股票概览与关键数据

BGM Group Ltd.（BGM）是 Drug Manufacturers - Specialty & Generic 行业的 Healthcare 类公司，于 Jan 24, 2003 在 NASDAQ 上市。截至最近交易日，BGM 股价为 $0.29，市值约为 $58.4M。过去12个月累计回报 -97.80%，年初至今回报 -92.11%。

2024 财年 BGM Group Ltd. 营收 $25.1M。完整财务数据（营收历史、盈利、资产负债表）请使用上方标签页。

常见问题

截至最近一个交易日，BGM Group Ltd.（BGM）股价为 $0.29，在 NASDAQ 上市，52周区间为 $0.26 – $17.17。

BGM 最新股价BGM quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议